MULTI-MODALITY MRI AND MRS FOR FUNCTIONAL ASSESSMENT OF BRAIN AND SPINAL CORD

用于脑和脊髓功能评估的多模态 MRI 和 MRS

基本信息

  • 批准号:
    7602570
  • 负责人:
  • 金额:
    $ 36.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-09-01 至 2008-08-31
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Clinical imaging studies still mainly rely on qualitative assessment of image features. When pediatric patients or neurodegenerative diseases are studied, this issue may become problematic, because changing brain features need not necessarily reflect changes in metabolic or physiological status. Conversely, pathological processes may on occasion manifest only as physiological changes without associated structural or anatomical abnormalities. The availability of quantitative absolute measures of physiological parameters, including metabolite concentrations, will therefore be extremely useful. Populations such as children or patients with dementia have reduced compliance for MRI exams, and it is crucial that imaging information can be obtained in a short period of time. Towards this goal, TRD2 was structured to develop techniques for fast quantitative MR spectroscopy (MRS) and spectroscopic imaging (MRSI), as reflected in the previous title Brain Chemistry by MR Spectroscopic Imaging. During the first grant period, we designed new approaches for rapid, quantitative spectroscopic imaging, using the SENSE parallel acquisition technique. We have succeeded in reducing the scan time for multi-slice MRSI from 30 minutes to about 10 min. However, there is still much to be improved, both in terms of the spatial resolution and speed of MRSI. In addition, the information content of MRSI is relatively limited, so there is a need for other, physiological imaging parameters that may provide additional data on disease pathophysiology, diagnosis or prognosis. For instance, our collaborators investigating demyelinating diseases such as Multiple Sclerosis (MS), adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN) have a need for imaging methodologies that provide more information on tissue myelin status and axonal integrity. Such information is also important for the study of normal and abnormal neurodevelopment in children, especially in the first years of life when the majority of myelination occurs. For instance, our clinical collaborators studying Cerebral Palsy (CP) and traumatic brain injury (TBI) in children would gain important information if they are able to judge white matter injury and development, in terms of both axonal integrity and myelin status. Spinal cord pathology is recognized to play an important role in clinical disability in diseases such as MS and ALD/ AMN, in some cases being the sole or primary site of involvement. Noninvasive measures of the integrity of axons and myelin in the spinal cord would be invaluable for assessing disease burden, tissue damage, and monitoring the effects of therapeutic interventions. However, the development of physiological neuroimaging techniques for the spine has lagged behind that in the brain. Our new KKI collaborator, Dr. McDonald, is setting up a spinal trauma program for children and his work would benefit tremendously from the capability to image spine metabolism and physiology. These and other collaborators have also wish to measure other physiological quantities in the spine, such as of blood flow, blood volume, and pH. As reflected in our new title, the overall goal of this TRD is therefore the design of such quantitative physiological MRI methodologies in both the brain and spine. AIM 1: Quantitative proton MRSI of the brain and spine at 3.0 Tesla and 7.0 Tesla Proton spectroscopy of the spine is in its infancy, and proton MRS of the brain at very high fields has to date been limited to single voxel studies. We will develop techniques for quantitative proton MRSI of the brain and cervical spinal cord at 3T and 7T. Much more than single-voxel MRS, multi-voxel approaches introduce technical challenges related to increased magnetic susceptibility effects and chemical shift displacement errors. Metabolite quantification suffers from B0 and B1 inhomogeneity. To address these issues, technique development is required in several respects. One area where we will focus is to exploit the synergy between parallel MR and high field acquisitions; we will explore self-calibrating parallel-MRSI schemes for improved SENSE-MRSI performance and reduced scan times. We will also develop MRSI processing software for use by the service and collaboration projects. AIM 2: Quantitative Magnetization Transfer Spectroscopy and Imaging of the brain and spine at 3.0 and 7.0 Tesla We will work on two types of magnetization transfer: 2A) Conventional MT imaging. We will implement high-resolution MT imaging at 7T and we will design imaging approaches for quantifying exchanges rates between the macromolecular phase and the free water pool. 2B) Amide Proton Transfer (APT) Imaging. We recently developed a new method capable of detecting mobile proteins and peptides in situ through the exchange between their amide protons and water protons. Animal studies using this APT contrast showed that the signal intensities in these images reflect pH and protein/peptide content. The goal is to implement this technology on the clinical scanners and explore its utility for the different diseases studies by our collaborators, including stroke, cancer, demyelination, and inflammation. Based on the type of contrast mechanism, this approach is expected to be more successful at high field. AIM 3: Development of novel non-invasive blood volume and blood flow imaging for clinical use at 1.5T, 3.0T, and 7.0T We will develop the use of blood-nulling techniques for the study of blood volume and blood flow imaging in situ. We will start out with the vascular-space occupancy (VASO) approach that we recently originated for fMRI, and implement practical multi-slice approaches for medical application with our collaborators. Recent calculations and subsequent data acquisitions show that the VASO contrast also contains a perfusion contribution, which we will call VAscular Space Labeling (VASL). The aim is to develop VASO and VASL to allow quantification of blood flow and blood volume in patients. These methods, which have relatively low signal-to-noise ratio (SNR) because of the low blood volume of normal brain, will become especially relevant at higher field where improved SNR is expected.
这个子项目是众多研究子项目之一

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PETER B BARKER其他文献

PETER B BARKER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PETER B BARKER', 18)}}的其他基金

Brain glutamine metabolism in schizophrenia
精神分裂症的脑谷氨酰胺代谢
  • 批准号:
    10286513
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Brain glutamine metabolism in schizophrenia
精神分裂症的脑谷氨酰胺代谢
  • 批准号:
    10467055
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Multi-voxel spectral editing at 3T
3T 多体素光谱编辑
  • 批准号:
    10316240
  • 财政年份:
    2020
  • 资助金额:
    $ 36.25万
  • 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
  • 批准号:
    8416461
  • 财政年份:
    2013
  • 资助金额:
    $ 36.25万
  • 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
  • 批准号:
    8890122
  • 财政年份:
    2013
  • 资助金额:
    $ 36.25万
  • 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
  • 批准号:
    8715738
  • 财政年份:
    2013
  • 资助金额:
    $ 36.25万
  • 项目类别:
Quantitative MRSI to predict early response to SAHA therapy in new GBM management
定量 MRSI 可预测新 GBM 治疗中 SAHA 治疗的早期反应
  • 批准号:
    9308872
  • 财政年份:
    2013
  • 资助金额:
    $ 36.25万
  • 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
  • 批准号:
    8492164
  • 财政年份:
    2012
  • 资助金额:
    $ 36.25万
  • 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
  • 批准号:
    8627212
  • 财政年份:
    2012
  • 资助金额:
    $ 36.25万
  • 项目类别:
Neurotransmitters in Schizophrenia using high-field MR Spectroscopy
使用高场磁共振波谱研究精神分裂症中的神经递质
  • 批准号:
    8391934
  • 财政年份:
    2012
  • 资助金额:
    $ 36.25万
  • 项目类别:

相似海外基金

Neurocognitive and neuroimaging markers of emerging cerebral adrenoleukodystrophy
新发脑性肾上腺脑白质营养不良的神经认知和神经影像学标志物
  • 批准号:
    10524184
  • 财政年份:
    2022
  • 资助金额:
    $ 36.25万
  • 项目类别:
Novel Role of Peroxisome Proliferator Activated Receptor Beta/Delta in X-Linked Adrenoleukodystrophy
过氧化物酶体增殖物激活受体β/δ在X连锁肾上腺脑白质营养不良中的新作用
  • 批准号:
    10312533
  • 财政年份:
    2022
  • 资助金额:
    $ 36.25万
  • 项目类别:
Novel Role of Peroxisome Proliferator Activated Receptor Beta/Delta in X-Linked Adrenoleukodystrophy
过氧化物酶体增殖物激活受体β/δ在X连锁肾上腺脑白质营养不良中的新作用
  • 批准号:
    10477980
  • 财政年份:
    2022
  • 资助金额:
    $ 36.25万
  • 项目类别:
Searching for biomarkers to discriminate the disease forms of adrenoleukodystrophy and to determine the indications for treatment
寻找生物标志物来区分肾上腺脑白质营养不良的疾病形式并确定治疗适应症
  • 批准号:
    22K07413
  • 财政年份:
    2022
  • 资助金额:
    $ 36.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Neurocognitive and neuroimaging markers of emerging cerebral adrenoleukodystrophy
新发脑性肾上腺脑白质营养不良的神经认知和神经影像学标志物
  • 批准号:
    10678672
  • 财政年份:
    2022
  • 资助金额:
    $ 36.25万
  • 项目类别:
Dose Optimization of Nervonic Acid - a Potential Therapy to Alleviate Disease Progression in Adrenoleukodystrophy
神经酸的剂量优化——缓解肾上腺脑白质营养不良疾病进展的潜在疗法
  • 批准号:
    10436950
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Leveraging myelin-sensitive imaging to predict early lesion pathogenesis in cerebral adrenoleukodystrophy
利用髓磷脂敏感成像预测脑肾上腺脑白质营养不良的早期病变发病机制
  • 批准号:
    10649537
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Leveraging myelin-sensitive imaging to predict early lesion pathogenesis in cerebral adrenoleukodystrophy
利用髓磷脂敏感成像预测脑肾上腺脑白质营养不良的早期病变发病机制
  • 批准号:
    10301855
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Use of IPSC to define role of astrocytes in specifying risk for onset of cerebral adrenoleukodystrophy
使用 IPSC 来定义星形胶质细胞在确定脑肾上腺脑白质营养不良发作风险中的作用
  • 批准号:
    10435433
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
Dose Optimization of Nervonic Acid - a Potential Therapy to Alleviate Disease Progression in Adrenoleukodystrophy
神经酸的剂量优化——缓解肾上腺脑白质营养不良疾病进展的潜在疗法
  • 批准号:
    10184383
  • 财政年份:
    2021
  • 资助金额:
    $ 36.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了